YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.

• Tác giả: Hua Han, Siyong Huang, Xinxin Li, Yanan Liang, Yingmin Liang, Shoubao Ma, Fengze Nie, Weihong Wen, Xianchun Yan, Zhiqiang Yin, Jianhua Yu, Minhua Zheng
• Ngôn ngữ: eng
• Thông tin xuất bản: England : Leukemia , 2025
• Bộ sưu tập: NCBI
• ID: 720191

Tóm tắt

B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive malignancy characterized by the aberrant accumulation of immature and dysfunctional B cells in bone marrow (BM). Although chemotherapy and other therapies have been widely applied, some patients such as relapsed or drug-refractory (R/R) B-ALL patients exhibit limited response. YT521-B homologous domain-containing protein 1 (YTHDC1) is a nuclear reader of N